WuXi Biologics Cayman Inc (Wuxi Biologics) is a contract research, development and manufacturing organization (CRDMO). It discovers, develops and manufactures biologics. The company offers protein generation, assay development, antibody generation, screening, characterization and optimization, regulatory affairs and testing services, among others. It utilizes the WuXiBody bispecific antibody platform and SDArBodY (single-domain antibody-related multispecific antibody) platform for bispecific and multispecific antibody discovery; WuXia cell line development platform; and WuXiUP continuous manufacturing platform. The company operates through its subsidiaries in China, Singapore, Ireland, Hong Kong, Germany and the US. Wuxi Bio is headquartered in Wuxi, Jiangsu, China.
Headquarters
China
Address
108 Meiliang Road, Mashan, Wuxi, Jiangsu, 214092
Website
www.wuxibiologics.com
No of Employees
12,740
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2269 (HKG)
Revenue (2022)
$2.4B
11.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-23.1%
(2022 vs 2021)
Market Cap*
$7.2B
Net Profit Margin (2022)
XYZ
-31.1%
(2022 vs 2021)
* As of and is in US$
WuXi Biologics Cayman Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Biologics | Contract Research, Development and Manufacturing | WuXiBody |
| Technology Platforms: | Protein Generation | WuXia |
| WuXiBody Bispecific Antibody Platform | Assay Development | SDArBodY |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In March, the company commenced the construction of a new 13.5-hectare CRDMO center in Tuas Biomedical Park, Singapore. |
| 2024 | Contracts/Agreements | In January, the company's Research Service Unit (R in CRDMO) entered into a research service agreement with BioNTech SE leveraging its proprietary antibody discovery technology platforms (R in CRDMO) to find two undisclosed targets of preclinical investigational monoclonal antibodies. |
| 2024 | Others | In January, the company completed the first manufacturing run at its drug substance facility MFG7, allowing for large-scale commercial manufacturing projects at the Ireland site. |
Competitor Comparison
| Key Parameters | WuXi Biologics Cayman Inc | Innovent Biologics Inc | Hainan Haiyao Co Ltd | Beijing SL Pharmaceutical Co Ltd | CanSino Biologics Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Wuxi | Suzhou | Haikou | Beijing | Tianjin |
| State/Province | Jiangsu | Jiangsu | Hainan | Beijing | Tianjin |
| No. of Employees | 12,740 | 4,872 | 2,247 | 757 | 1,494 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhisheng Chen | Director; Chief Executive Officer | Executive Board | 2016 | 50 |
| Ming Tu | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 54 |
| Sherry Gu, Ph.D. | Chief Technology Officer; Executive Vice President | Senior Management | - | - |
| He Daniel Wang | Chief Compliance Officer; Senior Vice President; Head - Global Compliance and Risk Management | Senior Management | - | - |
| Jijie Gu, Ph.D. | Chief Scientific Officer; President - Global Biologics Research | Senior Management | - | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward